Role of Interleukin-13 Pathways on Pain and Itch Sensitivity
Eligible age
18–60 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in both healthy subjects and people with atopic dermatitis.
Sponsor: Aalborg University
You may qualify if…
- ✓ Healthy men and women
- ✓ 18-60 years
You may not qualify if…
- ✕ Pregnancy or lactation
- ✕ Drug addiction defined as any use of cannabis, opioids, or other drugs
- ✕ Previous or current history of neurological, dermatological (e.g., AD, psoriasis, etc.), immunological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)
- ✕ Moles, wounds, scars, or tattoos in the area to be treated or tested
- ✕ Current use of medications that may affect the trial such as antihistamines and pain killers (use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment).
- ✕ Use of systemic and topical corticosteroids
- ✕ Consumption of alcohol or painkillers 24 hours before the study days and between these
- ✕ Acute or chronic pain
Source: ClinicalTrials.gov · NCT06503510 · last updated 2025-06-04